Form 4: Altimmune Names New CEO, Grants Significant Equity

Altimmune, Inc. announced the appointment of Jerome Benedict Durso as President and CEO effective January 1, 2026, accompanied by substantial equity awards.

Summary

• Jerome Benedict Durso has been appointed President and Chief Executive Officer of Altimmune, Inc., with his role becoming effective on January 1, 2026.
• He was granted 1,824,400 stock options with an exercise price of $4.93.
• These stock options will vest over four years, with 25% vesting on December 1, 2026, and the remaining portion vesting in equal monthly installments over the subsequent 36 months.
• Additionally, Mr. Durso received 633,700 Restricted Stock Units (RSUs).
• The RSUs will also vest over four years, with 25% vesting on December 1, 2026, and the remainder vesting in equal annual installments over the following three years.
• Both the stock options and RSUs are contingent upon Mr. Durso's continued service through each applicable vesting date.

Sentiment

Score: 7

Explanation: The appointment of a new CEO with significant equity incentives is generally a positive development, indicating a clear leadership transition and strong alignment of executive interests with long-term shareholder value through performance-based vesting.

Positives

• The appointment of Jerome Benedict Durso as President and CEO, effective January 1, 2026, signals new leadership and potential strategic direction for the company.
• Significant equity grants, including 1,824,400 stock options and 633,700 Restricted Stock Units, align the new CEO's long-term financial interests with shareholder value.
• The multi-year vesting schedules for both the stock options and RSUs are designed to incentivize sustained commitment and performance from the new CEO.

Future Outlook

The appointment of Jerome Benedict Durso as President and CEO effective January 1, 2026, along with substantial long-term equity incentives, indicates a strategic move to solidify leadership and drive future company performance. The vesting schedules are designed to ensure sustained commitment over the next four years.

Management Comments

• Mr. Durso has been appointed President and Chief Executive Officer of the Company effective January 1, 2026.

Industry Context

This filing represents a standard insider transaction disclosure following a significant executive appointment within the biotechnology or pharmaceutical industry. The granting of substantial equity awards is a common practice to attract and retain high-caliber leadership, aligning their long-term incentives with company performance and shareholder value, which is typical for growth-oriented companies in this sector.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Benefit from new leadership and incentive alignment through equity grants, potentially leading to improved long-term performance.
• Employees: Will operate under new executive leadership, which could bring changes in corporate culture, strategy, and operational focus.
• Management: The executive team will report to and work with the new CEO, potentially leading to shifts in roles or responsibilities.

Next Steps

• Jerome Benedict Durso will officially assume the role of President and Chief Executive Officer on January 1, 2026.
• The first tranche of stock options and Restricted Stock Units will vest on December 1, 2026.
• Subsequent vesting of stock options will occur in equal monthly installments over 36 months following December 1, 2026.
• Subsequent vesting of Restricted Stock Units will occur in equal annual installments over three years following December 1, 2026.

Key Dates

Keywords

Altimmune, ALT, CEO appointment, Jerome Benedict Durso, stock options, Restricted Stock Units, RSUs, insider transaction, executive compensation, corporate governance